| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.fredungroup.com | |
| Market Cap | 347.60 Cr. | |
| Enterprise Value(EV) | 432.66 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 21.73 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 35.30 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 32.17 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 188.86 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 4.06 | Calculated using Price: 766.95 |
| Dividend Yield | 0.09 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.45 Cr. | 4,532,272 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is engaged in manufacturing of pharmaceutical products. | ||
| 1 Day |
|
-4.88% |
| 1 Week |
|
-10.08% |
| 1 Month |
|
-9.94% |
| 3 Month |
|
-32.36% |
| 6 Month |
|
-27.62% |
| 1 Year |
|
-17.46% |
| 2 Year |
|
+63.80% |
| 5 Year |
|
+432.55% |
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 9.79 | 9.68 | 33.46 | 33.88 | 13.02 | 14.59 | 4.74 | 4.77 | 11.42 | |
| Return on Capital Employed (%) | 14.50 | 14.23 | 24.67 | 18.16 | 15.90 | 20.56 | 10.36 | 9.53 | 14.60 | |
| Return on Assets (%) | 1.50 | 1.26 | 3.23 | 2.88 | 2.59 | 4.84 | 1.54 | 1.33 | 3.63 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 3 | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 74 | |
| Non Curr. Liab. | 3 | 4 | 7 | 8 | 4 | 13 | 14 | 32 | 45 | 3 | |
| Curr. Liab. | 12 | 16 | 32 | 40 | 53 | 53 | 86 | 86 | 74 | 155 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 233 | |
| Non Curr. Assets | 8 | 10 | 15 | 21 | 28 | 32 | 32 | 32 | 34 | 37 | |
| Curr. Assets | 10 | 13 | 28 | 35 | 51 | 73 | 109 | 130 | 153 | 196 | |
| Misc. Exp. not W/O | 0 | ||||||||||
| Total Assets | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 233 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 21 | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 224 | 269 | |
| Other Income | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | ||
| Total Income | 22 | 26 | 43 | 59 | 60 | 98 | 113 | 135 | 226 | 269 | |
| Total Expenditure | -20 | -24 | -38 | -53 | -54 | -87 | -104 | -125 | -209 | -245 | |
| PBIDT | 2 | 2 | 5 | 5 | 6 | 11 | 9 | 11 | 17 | 23 | |
| Interest | -1 | -1 | -2 | -2 | -2 | -3 | -4 | -4 | -6 | -7 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -3 | |
| Taxation | 0 | 0 | -1 | -1 | -1 | -2 | -1 | -1 | -2 | -3 | |
| Exceptional Items | 0 | 0 | -1 | ||||||||
| PAT | 0 | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 10 | |
| Adjusted EPS | 1 | 1 | 4 | 5 | 4 | 11 | 5 | 5 | 14 | 22 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | -1 | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | |
| Cash Fr. Inv. | -1 | -2 | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | |
| Cash Fr. Finan. | 0 | 2 | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | |
| Net Change | 0 | 0 | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | |
| Cash & Cash Eqvt | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 |
|
Tue, 21 Feb 2023
Announcement under Regulation 30 (LODR)-Investor Presentation Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewiththe Investor Presentation. |
|
Sat, 28 Jan 2023
Revised Financial Results For Quarter Ended December 31 2022 We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company) at their Meeting held on Friday 27th January 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by M/s. Savla & Associates Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M. |
|
Sat, 28 Jan 2023
Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 27Th January 2023 Revised outcome of the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company) at their Meeting held on Friday 27th January 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by M/s. Savla & Associates Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M. |
| Wed, 29 Mar 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors